The Relationships Between MASLD, Extrahepatic Multimorbidity, and All-Cause Mortality in the UK Biobank Cohort
-
By
-
Qi Feng
-
Chioma N Izzi-Engbeaya
-
Andrea D Branch
-
Benjamin H Mullish
-
Pinelopi Manousou
-
Mark Woodward
-
June 10, 2025
-
Objective:
To estimate the impact of MASLD, with and without multimorbidity, on all-cause mortality.
Key Findings:
- Participants with MASLD had a higher prevalence of multimorbidity (21.3% vs 14.4%).
- MASLD was associated with a 16% higher mortality rate (HR 1.16; 95% CI 1.13, 1.19).
- Each additional LTC at baseline was linked to 30% higher mortality in MASLD and 38% in non-MASLD populations.
- 16 out of 47 LTCs were associated with increased mortality in individuals with MASLD.
Interpretation:
MASLD significantly contributes to extrahepatic multimorbidity and mortality, highlighting the need for targeted interventions.
Limitations:
- Study limited to participants aged 40-70 years, potentially affecting generalizability.
- Reliance on self-reported data for some health conditions may introduce bias.
Conclusion:
The study underscores the importance of addressing MASLD and associated multimorbidities to improve health outcomes and reduce healthcare burdens.
